Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Hurricanes maintain unbeaten run in dominant win over ChiefsGuest Opinion: Xi's message to AmericansEast China's Suzhou to hold cultural event in SingaporeXinhua Commentary: Xi's meeting with Ma injects positive energy to relations across Taiwan StraitNewsmakers1.334 bln people covered by China's basic medical insuranceCommentary: Chinese economy ascending, not peakingFeature: ChinaUAE to participate in 21st ChinaChina, South Australia to deepen cooperation
3.4976s , 6490.953125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Grounds news portal